PFAS Health Risks: Cancer, Hormones, and What the Science Actually Says
In 2023, the International Agency for Research on Cancer — the World Health Organization body responsible for evaluating carcinogenic hazards — classified PFOA as a Group 1 carcinogen: carcinogenic to humans. This placed PFOA in the same category as asbestos, tobacco smoke, and benzene. The classification came after decades of epidemiological and experimental evidence accumulated in communities living near fluorochemical manufacturing sites, most notably the C8 cohort of 69,000 people in the United States followed by researchers from West Virginia University over twenty years.
Cancer is not the only health concern. The body of scientific literature on PFAS health effects now spans thyroid hormone disruption, cardiovascular damage, suppression of vaccine-induced immunity, reproductive harm, and developmental effects in children. The breadth of these effects reflects the fact that PFAS — once absorbed — bind to proteins throughout the body and accumulate in multiple organ systems over a lifetime of chronic low-level exposure.
This article summarises the current state of the science on each major health endpoint, with specific reference to the studies and regulatory assessments that form the evidentiary basis. Understanding the mechanisms of harm is the foundation for understanding why filtration at the point of water entry is a meaningful protective measure.
How PFAS Behave Inside the Human Body
PFAS are persistent organic pollutants — a designation that means they do not break down in biological systems. Once ingested, they are absorbed through the gastrointestinal tract and distribute primarily to the blood, where they bind tightly to serum albumin, the most abundant protein in plasma. From the bloodstream they distribute to the liver, kidneys, thyroid gland, and reproductive organs. PFAS are not metabolised: the body has no enzymatic pathway capable of breaking the carbon–fluorine bond. Excretion occurs slowly through urine, bile, and faeces, but the rate of accumulation from chronic daily exposure through drinking water and food exceeds the rate of elimination for most people.
The half-life of PFOS in human serum — the time taken for the body burden to fall by half in the absence of new exposure — is approximately 5.4 years according to WHO International Programme on Chemical Safety (IPCS) assessments. For PFOA, the serum half-life is approximately 3.5 years. This means that even if all PFAS exposure stopped today, a significant proportion of the accumulated body burden would remain for a decade. For people with continuous low-level exposure through drinking water, the body burden does not decline — it accumulates incrementally over decades.
This pharmacokinetic profile — persistent, protein-binding, and organ-accumulating — is the mechanistic foundation for the diverse health effects observed. PFAS interfere with protein function wherever they accumulate: disrupting thyroid hormone transport proteins, interfering with lipid metabolism enzymes in the liver, and altering immune cell signalling pathways. Understanding the body-burden dynamics also explains why regulatory agencies express tolerable intake as a weekly rather than daily figure: the relevant exposure metric is cumulative burden, not any single day's intake.
Cancer — IARC Group 1 Classification and the Evidence
In July 2023, the IARC Monographs Programme classified PFOA as a Group 1 human carcinogen and PFOS as a Group 2B possible carcinogen (IARC Monographs Volume 135, 2023). The Group 1 classification for PFOA was based on sufficient evidence of carcinogenicity in humans, with the strongest associations for kidney cancer and testicular cancer. The C8 Health Project — the largest PFAS epidemiological study ever conducted, following the 69,000-person community exposed to PFOA from the DuPont Washington Works facility in West Virginia — provided the core epidemiological evidence, supported by mechanistic data from animal studies showing consistent tumour induction at multiple sites.
Kidney cancer and testicular cancer have the most robust evidence base. The C8 Science Panel — six epidemiologists appointed jointly by plaintiffs and DuPont to evaluate the cohort data — found a "probable link" between PFOA exposure and kidney cancer, testicular cancer, ulcerative colitis, thyroid disease, hypercholesterolaemia, and pregnancy-induced hypertension. The IARC 2023 review additionally identified emerging evidence for associations between PFAS exposure and bladder cancer, breast cancer, and non-Hodgkin lymphoma, though these were classified as limited evidence and require further study.
The mechanisms proposed include activation of nuclear receptors (particularly peroxisome proliferator-activated receptors, PPARs) that regulate cell growth and differentiation, oxidative stress, DNA damage signalling pathway disruption, and epigenetic modifications. The PFOS Group 2B classification reflects a smaller but growing body of evidence; the difference from PFOA's Group 1 reflects the quantity and consistency of human data available at the time of evaluation, not a conclusion that PFOS is categorically safer.
Thyroid Hormone Disruption
The thyroid gland is one of the most sensitive targets of PFAS toxicity. PFAS, particularly PFOA and PFOS, compete with thyroid hormones for binding to thyroid hormone transport proteins including transthyretin and thyroid-binding globulin. This competition reduces the availability of free thyroid hormones — thyroxine (T4) and triiodothyronine (T3) — that are essential for metabolism, cognitive function, and development.
The European Food Safety Authority's 2020 comprehensive risk assessment — which established the tolerable weekly intake that is now the most widely cited European reference point for PFAS health guidance — identified immune effects in children as the most sensitive endpoint, but thyroid disruption emerged as a significant concern, particularly for infants and foetuses. The EFSA assessment cited studies associating PFAS exposure with reduced thyroid stimulating hormone (TSH) concentrations in newborns and with clinical hypothyroidism in adults (EFSA Journal 18(9):e06223, 2020).
Thyroid disruption has consequences beyond the thyroid itself. In foetuses and infants, adequate thyroid hormone levels are critical for brain development, neuronal migration, and myelination. Subclinical hypothyroidism in pregnant women has been associated with lower IQ scores in offspring in independent cohort studies. The thyroid pathway is one of the primary reasons that pregnant women and newborns are identified as the highest-risk subgroups for PFAS health effects.
Cardiovascular and Metabolic Effects
Multiple large epidemiological studies have found associations between serum PFAS concentrations and elevated total cholesterol, LDL cholesterol, and triglycerides. The C8 Health Project found statistically significant associations between PFOA exposure and elevated total cholesterol in over 46,000 participants — one of the most robust epidemiological findings in the PFAS literature. Danish cohort studies, including data from the Danish National Birth Cohort, have replicated the cholesterol-PFAS association in European populations with lower background exposure levels.
The proposed mechanism involves PFAS interference with lipid metabolism enzymes in the liver, particularly those regulated by PPAR-alpha, which controls fatty acid oxidation and lipoprotein synthesis. Elevated LDL and triglycerides are established risk factors for atherosclerosis and cardiovascular disease. While the absolute PFAS-attributable cardiovascular risk at typical environmental exposure levels remains under quantification, the consistency of the cholesterol association across study populations makes it one of the most replicated PFAS health findings.
Research published in Environmental Health Perspectives has also associated higher PFAS serum concentrations with elevated uric acid levels, a risk factor for gout and a marker of impaired renal tubular secretion. The kidney is both a target organ for PFAS accumulation and a route of excretion; PFAS-associated kidney impairment at subclinical levels may contribute to the broader metabolic profile observed in exposed populations.
Immune Suppression and Reduced Vaccine Effectiveness
One of the most consequential findings in PFAS research — and the primary driver of EFSA's 2020 tolerable weekly intake — is the evidence that PFAS suppress vaccine-induced antibody responses in children. A landmark study by Grandjean et al. published in The Lancet in 2012 measured antibody titres to diphtheria and tetanus vaccines in 587 children from the Faroe Islands cohort and found that each doubling of PFAS concentration in serum at age 5 was associated with approximately halved antibody concentrations at age 7. Children with the highest PFAS exposures had antibody levels below the threshold considered protective against disease.
The EFSA Panel on Contaminants in the Food Chain reviewed the available immunotoxicity literature in detail and concluded that reduced vaccine response in children was the most sensitive adverse effect — meaning it occurred at lower exposure levels than any other documented health outcome, including the lipid effects and thyroid effects described above. This is why EFSA set a tolerable weekly intake of 4.4 ng per kilogram of body weight per week for the sum of PFOS, PFOA, PFHxS, and PFNA — a figure intended to protect the most sensitive members of the population, namely infants and children with developing immune systems (EFSA Journal 18(9):e06223, 2020).
The immunotoxicity pathway is thought to involve PFAS interference with natural killer cell activity, T-lymphocyte signalling, and cytokine production. Animal data from the US National Toxicology Program (NTP, 2016) demonstrated consistent immune suppression in rodents at environmentally relevant exposures, providing mechanistic corroboration for the human epidemiological findings. The implication for public health is significant: reduced vaccine effectiveness means that PFAS-exposed children may not be adequately protected by routine immunisation programmes even when vaccination coverage is high.
Reproductive and Developmental Harm
PFAS exposure has been associated with a range of reproductive and developmental outcomes across multiple study populations. For women, associations include reduced fertility (longer time-to-pregnancy), pregnancy-induced hypertension, preeclampsia, gestational diabetes, and earlier onset of menopause. For men, PFAS have been associated with reduced sperm quality — lower concentration, motility, and normal morphology — in studies from the Danish National Birth Cohort and European Human Early-Life Exposome (HELIX) project.
Foetal and infant effects represent a particularly concerning dimension. PFAS cross the placental barrier and are present in breast milk, meaning that exposure begins before birth and continues through early infancy during the period of most rapid development. Studies have found associations between maternal PFAS serum levels and reduced birth weight, shorter gestational age, and reduced head circumference — markers of impaired intrauterine growth. The Norwegian Mother and Child Cohort study found associations between prenatal PFAS exposure and neurodevelopmental outcomes including attention deficit problems and language delays in early childhood.
Polycystic ovary syndrome (PCOS) has also been associated with PFAS exposure in mechanistic research, consistent with the known endocrine-disrupting properties of these compounds. The reproductive effects span both sexes, both the conception phase and pregnancy, and extend into early childhood development — underscoring why public health guidelines identify pregnant women, women planning pregnancy, and infants as priority groups for PFAS exposure reduction.
Exposure Routes Beyond Drinking Water
Drinking water is a significant and controllable exposure pathway, but it is not the only one. Food contact materials are a major source: grease-proof food packaging, microwave popcorn bags, and fast-food wrappers have historically used PFAS-based coatings, and migration of PFAS into food during heating has been documented in peer-reviewed research. Non-stick cookware manufactured with PTFE (polytetrafluoroethylene) releases PFAS breakdown products when overheated above approximately 260°C.
Stain-resistant textiles treated with PFAS — including some upholstered furniture, carpets, and outdoor clothing — shed PFAS into household dust, where ingestion by children through hand-to-mouth contact is a documented exposure pathway. Some PTFE-coated dental floss products have been found to elevate serum PFAS concentrations. Cosmetics and personal care products containing PTFE or ingredients labelled with "fluoro" prefixes are an emerging area of concern.
Understanding that PFAS exposure comes from multiple directions does not diminish the importance of filtering drinking water — it means that reducing the drinking water contribution is one of the most actionable steps available, since it is the one most directly within an individual's control. Filtration at the point of entry into the home treats all water used for drinking, cooking, and preparation of infant formula and food, addressing the largest and most consistently ingested source at one location.
Protect your household from PFAS accumulation with ETH Zurich-validated whole-home filtration.
Explore the Essential PlusRelated Resources
Frequently Asked Questions
Is PFOA classified as a carcinogen?
Yes. The International Agency for Research on Cancer (IARC) classified PFOA as a Group 1 carcinogen — carcinogenic to humans — in 2023 based on sufficient evidence for kidney and testicular cancer. PFOS was classified as Group 2B (possibly carcinogenic). IARC Monographs Volume 135 contains the full evaluation.
What is the main PFAS health risk that regulators are most concerned about?
The European Food Safety Authority (EFSA) identified reduced vaccine antibody response in children as the most sensitive adverse health effect — meaning it occurs at lower PFAS exposure levels than cancer or other outcomes. This finding drove EFSA's 2020 tolerable weekly intake of 4.4 ng/kg body weight per week for the sum of four key PFAS.
Does PFAS exposure cause thyroid problems?
PFAS compete with thyroid hormones for binding to transport proteins, reducing circulating free thyroid hormone concentrations. EFSA's 2020 assessment associated PFAS exposure with reduced TSH in infants and with clinical thyroid disease in adults. The effect is particularly significant during pregnancy and early childhood, when thyroid hormones are critical for brain development.
Are children more at risk from PFAS than adults?
Yes. Children are at higher risk for several reasons: they ingest more water relative to body weight; they are in critical developmental windows for the brain, immune system, and reproductive organs; PFAS cross the placental barrier and are present in breast milk; and the immune suppression effects documented by Grandjean et al. (Lancet, 2012) are most pronounced in infants and young children.
Can filtering drinking water meaningfully reduce PFAS health risks?
Yes. Drinking water is one of the most consistently significant PFAS exposure pathways for most households, and it is the most directly controllable. Adsorption filtration validated by ETH Zurich University achieves greater than 96 to 98.5 percent PFAS removal in a single pass. Reducing daily drinking water PFAS intake prevents incremental accumulation in blood and organs over the years and decades that determine long-term body burden.
Sources & References
- IARC (2023). Perfluorooctanoic acid (PFOA) and Perfluorooctane sulfonic acid (PFOS). IARC Monographs on the Identification of Carcinogenic Hazards to Humans, Volume 135.
- EFSA (2020). Risk to human health related to the presence of perfluoroalkyl substances in food. EFSA Journal 18(9):e06223.
- Grandjean P. et al. (2012). Serum vaccine antibody concentrations in children exposed to perfluorinated compounds. JAMA 307(4):391–397.
- US National Toxicology Program (2016). Immunotoxicity Associated with Exposure to Perfluorooctanoic Acid or Perfluorooctane Sulfonate. NTP Technical Report 598.
- WHO/IPCS (2008). Perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA) and their salts. Environmental Health Criteria 239.